Try our Advanced Search for more refined results
Life Sciences - February, 2013
243 articles
- Top Plaintiffs Firms Say Amgen No License To Print Money
- Takeda Failed To Warn Of Actos Cancer Risk, Jury Hears
- Amgen Dissents Put Fraud On The Market On Thin Ice
- Merck Criticizes FTC's Proposed Pay-For-Delay Rule
- Icahn Gains Two Herbalife Directors In Feud With Ackman
- Bayer Budgeted $1.6B For Yaz, Yasmin Suits
- Warner Chilcott Says Contracts Bar Retailers' Doryx Suit
- Texas Appeals Court Nixes $10M Award Against Fen-Phen Atty
- DePuy Should Pay $23M Over Faulty Hip Implant, Jury Told
- J&J Hit With $7.8M Punitive Award Over Vaginal Mesh Product
- CMS Escapes DME Bidding Dispute Despite Judge's Rebuke
- Skadden Reps Mylan In $1.6B Buy Of Indian Generics Maker
- PerkinElmer — A Sign Of What's To Come For Diagnostics
- 6 Areas Often Underestimated In Law Firm Mergers
- DePuy Plaintiff's Metal Hip Didn't Need Replacing, Jury Hears
- Amgen's High Court Defeat Leaves Defense Bar Reeling
- 1st Thoughts On Supreme Court's Amgen Ruling
- FDA Issues Pediatric Drug Labeling Guidelines
- GSK Not Immune To Drug-Discount Antitrust Suit, Clinic Says
- Employers Ask Supreme Court To Find DOMA Unconstitutional
- Alcon Accused Of Selling Big Bottles To Boost Profits
- How Inter Partes Review Impacts Hatch-Waxman Exclusivity
- High Court Rebuffs Amgen, Lowering Bar For Investor Suits
- Pfizer Gets New Trial After $39M Trade Secrets Verdict
- NJ Jury Mulls Punitive Damages In J&J Vaginal Mesh Trial
- Vaginal Mesh Injuries Strike A Chord With Jurors
- Judge Axes $500M FCA Suit Over Public Info-Based Claims
- Surgeon Says DePuy Hip Implant Was Thoroughly Tested
- Device Industry Vows To 'Double Down' On Tax Repeal
- FDA Sets Child Safety Rule After Death In Amgen Trial
- FDA Warns Supplement Co. Over Facebook 'Like'
- Endurance Doesn't Owe Defense In Pollution Control Suit
- Quigley To Make Another Bid For Plan Confirmation In June
- Reed Smith Says Howdy To Houston With 12-Partner Office
- Daubert-Style Gatekeeping In Calif.? Not Quite
- Eli Lilly Can't Escape Class Action Over Cymbalta Labeling
- Shine Might Be Off Alt Fee Arrangements, GC Survey Shows
- GCs Brace For More Whistleblower Suits
- In-House Teams Expand To Keep Pace With More Suits, Probes
- BioClinica Shareholders Can't Stop $123M PE Takeover Bid
- GCs Rate Fixed Fees Best Bang For Their Buck
- DePuy Hip Failure Due To Incorrect Angle, Jury Hears
- Patheon Can't Duck JV Partner's Suit Over $255M Acquisition
- Enema Maker Claims Rival Defamed Its Product To VA
- FDA Eyes New Rule For Foreign Clinical Data On Devices
- Medicare Could Save $14M With Drug Price Controls: Report
- DePuy Knee Joint Part Recalled Over Fracture Risk
- Pharma Execs Can't Duck Prosecutors With Off-Label Ruling
- Dynavax's Hep B Vaccine Doesn't Pass Muster With FDA
- High Court Won't Weigh UnitedHealth ERISA Preemption Case
- J&J Hit With $3.35M Verdict In Vaginal Mesh Bellwether
- FDA Refers Reckitt To FTC For Hindering Generic Suboxone
- Royalty Pharma Lobs $6.6B Takeover Bid At Elan
- Pharma Cos., Scan Your Drugs For Proper Barcodes
- Firms End Battle Royal Over $4M Pfizer Settlement Fees
- Vinson & Elkins Won't Be Booted From Galderma IP Suit
- Compounding Group Open To Oversight Talks With FDA
- Warner Chilcott Falsely Promoted Drugs, FCA Suit Says
- 6th Circ. Resurrects Vitamin C Labeling Suit Against P&G
- DePuy Designer Blames Some Surgeons For Hip Failures
- UK Court Sides With Genentech In Eye-Treatment Patent Suit
- J&J Reveals Gov't Probes Of Hip Implant, Surgical Mesh
- Novartis Sues To Block Generic Reclast, Zometa Drugs
- Dialysis Industry Continues To See Robust PE Activity
- FDA Chief Warns Generics Industry On Safety Lapses
- Merck, Pa. Reach $8.25M Settlement Over Vioxx Disclosures
- A Food Industry Issue Menu For 2013: Part 2
- Calif. Lawmaker Floats Genetic Privacy Bill Again
- Pharma Cos. Rip FTC's Bid To Bar Pay-For-Delay Deals
- Ky. Adds To GSK's Avandia Woes With 2nd State Suit
- LabCorp Ducks Some Stanford Claims In Prenatal Test IP Row
- Teva Slams Antitrust Claims In Azilect Patent Row
- Leibowitz Tells Law360 He's Leaving FTC In Good Shape
- Medical Device Co. Sanctioned For Iran Exports
- US Wants Voice In Supreme Court Generic-Drug Showdown
- DePuy's Metal Hip Implant Wasn't Poisonous, Expert Says
- German Co. Beats AntiCancer's Tumor Imaging Patent Suit
- Travelers Sues To Dodge Coverage In Medical Device IP Row
- Successful Life Science Collaborations Require Flexibility
- Maryland AG Hits GSK With Avandia False Claims Suit
- 3rd Circ. Reinstates Former Teleflex Exec's Age Bias Case
- Medicare Heavily Overpaid For Infusion Drugs, Report Says
- FDA Warns Against Post-Surgery Use Of Codeine In Kids
- Complete Genomics Says Its Probes Differ From Illumina's
- Teva Settles Gilead's HIV Drug Patent Suit As Trial Looms
- Hogan Lovells Snags Drug Regulatory Pro From Sidley Austin
- Ranbaxy Attacks Recall Demand In Glass Particles Action
- Diagnostics Co. Hycor Unloads Unit In Sale To PE Group
- How EPA Will Clean Things Up In 2013
- Herbalife Confirms SEC Probe Into Finances
- DePuy Reps Didn't Report Hip Implant Complaints, Jury Hears
- Pfizer Asks Ala. Top Court To Undo Generics Liability Ruling
- FDA Says Device Makers Must Provide Pediatric Data
- Pillsbury Adds Ex-Crowell & Moring Health Partner In DC
- Look Out For Possible Changes In Energy Drink Industry
- Smith & Nephew Sued Over Painful Hip Replacement
- Terumo Targets Rivals Over Catheterization Device IP
- Novartis Kills $78M Noncompete Deal With Departing Chairman
- Calif. Class Certified In Arthritis Drink False Ad Suit
- Novartis Beats Osteoporosis Drug Injury Suit
- Things To Keep In Mind When Marking Your Pot
- J&J Vaginal Mesh Warnings Debated In Closing Args
- Valeant Pays $12M To Settle Wellbutrin Antitrust Claims
- Lawmakers Urge FDA To Stiffen Hydrocodone Controls
- Roche Escapes 40 Accutane MDL Suits Due To Lack Of Expert
- FDA Gets Dozens Of Complaints After Ranbaxy Recall
- Bristol-Myers Dodges 24 Wrongful Death Suits Over Toxins
- GCs Name 43 Best-Of-The-Best Attys
- Aussie Court Upholds Myriad's Breast Cancer Gene Patent
- No Touch Up On 'Natural' Beauty By Calif. Court
- Icahn Reveals 13% Herbalife Stake, Heats Up Ackman Feud
- Sandoz, Intas Can't Ditch Merck's Suit Over Generic Emend
- GCs Name Cream Of The Crop Litigators
- GSK Wants Out Of HIV Drug Kickback Suit
- Divergent Approaches To Claim Construction
- Fed. Circ. Backs AstraZeneca Win In Seroquel XR Patent Row
- Office Campus Plans In $4B SF Project Get Panel's OK
- Record $688M Merck Settlement May Not Be Contagious
- Impax's Appeal Too Late In Amrix Case, Fed. Circ. Says
- Generic Fentora Doesn't Violate Teva IP, Fed. Circ. Finds
- Covidien Sues Former Sales Rep For Jumping To Abbott
- Reckitt Kept Addiction Drugs Off Market: Antitrust Suit
- Cardinal Health Puts Up $2B For PE-Backed AssuraMed
- Senate's Pay-For-Delay Bill Would Weaken Drug Patents
- Merck To Pay $688M To Settle Investor Suits Over Vytorin
- DePuy Exec Says He Knew Of Safety Concerns For Hip Implant
- Walgreen Co. Can't Trademark Store-Brand Zyrtec
- Drug Industry Warns Against Medicare Part D Rebates
- Drug Cos. Faulted For Not Giving FDA Risky-Drug Info
- Judge Refuses To Step Down From NJ Accutane Cases
- Upsher, Forest Ink $11M Drug Price Inflation Settlement
- J&J Hit With $63M Verdict Over Children's Motrin Warning
- FDA Review Adds To Hospira's Regulatory Woes
- US Needs Drug Tracking System To Stop Counterfeits: Report
- Travelers' Suit Dropped From Neurontin MDL
- Panel Centers NECC Meningitis Cases In Mass., Not Minn.
- JPML Combines 9 Plavix Injury, FCA Actions In NJ
- A Food Industry Issue Menu For 2013: Part 1
- Enzo Again Hits Abbott With Patent Suit Over DNA Probes
- Generics Primed To Fight FDA On Labeling Flexibility
- BioZone Founder's $30M Suit Survives Forum Challenge
- Bristol-Myers Inks $440M Sales Deal With Reckitt Benckiser
- Primary Jurisdiction May Be Useful In Food Labeling Cases
- Union Sues FDA Demanding Full Report On St. Jude Probe
- States Ask 8th Circ. To Pause ACA Contraception Rule Appeal
- Mass Tort Reforms Prompt Fewer Filings, Philly Judge Reports
- WL Gore Fights Bard's Antitrust Claims In Stent Patent Case
- Fed. Circ. Affirms Boston Scientific's $42M Patent Win
- Gov't Can Depose Guidant Workers In $726M FCA Suit: Judge
- Illumina Sued For Rejecting Roche Bids That Topped $8B
- Judge Invalidates Bristol-Myers Patent For Hepatitis B Drug
- DePuy Hip Implant 'Poisoned' Dad, Daughter Testifies
- GSK Win In Paxil Suicide Case Upheld In NM Court
- 3rd Circ. Urged Not To Halt Antitrust Suit Over GSK Drug
- FDA Mulls Dramatic Shift In Generic-Drug Labeling Regs
- Fresenius Hid Cardiac Risks Of Dialysis Treatment, Suit Says
- Coke, GSK Dodge Cleanup Claims Over Ohio Landfill
- ABA Will Back Myriad's Gene Patents In Supreme Court
- Celgene Cancer Drug Makes Regulatory Strides In China, US
- U Of Illinois' Immunity Dooms Patent Challenge, Judge Says
- FDA Delays Novo Diabetes Drugs Over Heart Risks
- Drugmaker Paid Women Less Than Men, $100M Bias Suit Says
- Law360 Life Sciences Editorial Advisory Board
- GSK Lobs False Ad Suit At Teva Over Axed Wellbutrin Generic
- Ready Or Not, Final Compliance Guidelines Are Here
- XL Needn't Waive Deductible, Limits In Stryker Case: Judge
- Novartis Asks High Court To Restore Allergy Drug Patent
- No Space For Partner Egos In Law Firm Of The Future
- White House Says Sequester Threatens Drug Approvals
- Novartis Can't Shake $1M Aredia, Zometa Verdict In 4th Circ.
- AstraZeneca, Torrent Settle Time-Release Seroquel IP Row
- FDA Tells 2nd Circ. It's Not Bound To Feed Antibiotics Ban
- Drugmaker Titan Ordered To Shut Down U.S. Operations
- Par Pharma Sued Over Plans For Generic Constipation Drug
- AmerisourceBergen Sued Over CEO's Hefty Stock Payout
- 3SBio Valued At $350M In Go-Private Sale To CEO, PE Firm
- Shire Pays $48M To End Adderall Supply Suit
- A Defendant's Guide To Approaching Head Injury Cases
- SunPharma Strikes Out Again With $600M Taro Offer
- Catholic Leaders Reject ACA Contraceptive Compromise
- Pfizer Notes Doctor Decisions In Appeal Of $142M RICO Award
- FDA Pushes New Approach To Alzheimer's Drug Development
- DePuy Hip Implants Failed At Troubling Rate, Doc Testifies
- Docs Fear For Reputations Under Final Sunshine Rule
- Fed. Circ. Affirms Merck Win In Vytorin, Zetia Patent Case
- Ackman Has More Questions On Herbalife's Biz Model
- Breg Wins Bellwether Trial In Calif. Pain Pump Suits
- Teva Can't Swap Out Expert In HIV Drug Patent Trial
- AstraZeneca Ends Ky. AG's Seroquel Suit With $5.5M Deal
- Glenmark Sinks GSK Malaria Drug Patent In UK Court
- Human Genes Shouldn't Be Patented, DNA Pioneer Says
- CORRECTED: Jones Day Lands 2 M&A Pros For New Amsterdam Branch
- GSK Accused Of Ripping Off La. Medicaid Programs
- FDA's Label Directive Pumps Up Plaintiffs In Drug Suits
- House Bill Would End $29B Medical Device Excise Tax
- FDA Warns Clinics About New Bogus Batches Of Avastin
- Patent Re-Exams Can Rebut Willful Infringement, Cordis Says
- Warner Chilcott Faces Fresh Suit Over Doryx Generic Ploy
- DePuy Hip Deformity Rate Was Alarming, Expert Tells Jury
- Forest Labs Wants Class Nixed In $100M Gender Bias Suit
- Biogen Pays $3.25B For Stake In Elan's MS Drug
- Wyeth V. Weeks: Implications For Pharma Manufacturers
- Judge Denies Class Cert. In Antidepressant Marketing MDL
- Final Sunshine Rule Gives Doctors More Room To Experiment
- House OKs Bills To Boost Pediatric Training, Research
- FDA Aims To Invigorate Sluggish Drug-Labeling Overhaul
- Mylan Says Unnamed Inventor Invalidates Merck Vytorin Patent
- Stryker Wins $70M Jury Verdict In Zimmer Patent Suit
- Sens. Introduce Bill To Ban Pay-For-Delay Deals
- Med Journal Rule Harms Patient Privacy, Pharma Group Says
- FDA Generics Process Not Bound By 'Fairness,' DC Circ. Told
- Merck Loses Final Bellwether Trial In Fosamax MDL
- 1st Circ. Revives Investors' Feraheme Risks Class Action
- FDA Warns Novo On Drug Contamination Measures
- GSK Puts Up $900M To Boost Stake In Indian Unit
- Cadence Sues Sandoz Over Generic Ofirmev Plans
- Calif. Takes Stab At Its Own Essential Health Benefits
- Exploiting Calif.'s 'All Natural' Food Craze
- BioClinica Investor Wants $123M PE Takeover Put On Ice
- Birth Control Compromise Hard Pill For Insurers To Swallow
- Purdue Sues To Block Abuse-Proof OxyContin Generics
- Mylan Pushes Fed. Circ. To Revive 5 COPD Drug Patents
- New Drug Pathway Must Weigh Risk, Off-Label Use, FDA Hears
- Zicam Maker Pays $4.5M To Snuff Stock Fraud Suit
- Sanofi, BMS Sued By W.Va. AG Over Plavix Marketing
- GOP Threatens To Compel FDA Compounding Pharmacy Docs
- Challenging Ex Parte Communications With Physicians
- 2nd Circ. Won't Revive Elan, Pfizer Investor Row
- European Device Group Pushes For Changes To New EU Regs
- Roche's Real Aim In Recusal Bid May Be To Chasten Judge
- Obama's Compromise On Contraception Won't End Lawsuits
- Merck Claims Ky. AG Knows Nothing About Vioxx Prosecution
- J&J Unit Beats TCPA Junk Fax Class Action
- State Biosimilar Bills Pose New Threat To Budding Industry
- Feds Unveil ACA's Long-Delayed Doc Payment Sunshine Rule
- DePuy Hip Failure Caused By Metal Toxins, Jury Told
- US Tells High Court Myriad's Isolated DNA Can't Be Patented
- Shire Pays $57.5M To End ADHD Drug Marketing Probe
- Eisai Beats Whistleblower's Off-Label Marketing FCA Suit
- Pfizer Escapes Discrimination Suit Alleging Racism, Ageism
- A Prescription To Treat Reputational Ills In Pharma Cos.
- HHS Proposes Contraception Mandate Opt-Out
- J&J Ordered To Pay $181M In Attys' Fees In Risperdal Suit